|

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

RECRUITINGPhase 4Sponsored by CHU de Quebec-Universite Laval
Actively Recruiting
PhasePhase 4
SponsorCHU de Quebec-Universite Laval
Started2026-01-05
Est. completion2028-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07094048

Summary

Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Multiple myeloma patient:
* ≥ 18 years old
* ≥ 1 prior lines of therapy
* Receiving a BCMA-directed T-cell Engager therapy (starting on treatment)
* On previous Ig support or not

Exclusion Criteria:

* Less than 18 years old
* Pregancy or breastfeeding

Conditions3

CancerMultiple Myeloma, RefractoryRelapsed Multiple Myeloma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.